Health Care & Life Sciences » Biotechnology | MultiCell Technologies Inc.

MultiCell Technologies Inc. | Balance Sheet

Fiscal year is December-November. All values USD Thousands.
2010
2011
2012
2013
2014
Cash & Short Term Investments
634.40
405.30
199.50
146.20
112.50
Total Accounts Receivable
31.00
303.10
-
-
-
Other Current Assets
8.90
10.60
11.30
32.60
13.40
Total Current Assets
674.30
719.00
210.80
178.80
125.90
Net Property, Plant & Equipment
1.10
-
-
-
-
Other Assets
1.70
1.70
0.30
0.30
0.30
Total Assets
677.10
720.70
211.00
179.10
126.20
ST Debt & Current Portion LT Debt
-
-
50.00
45.10
-
Accounts Payable
1,677.00
1,354.40
1,106.20
1,072.50
750.50
Other Current Liabilities
287.20
351.20
99.30
161.30
430.70
Total Current Liabilities
1,964.20
1,705.70
1,255.50
1,278.90
1,181.10
Long-Term Debt
50.70
59.60
56.00
-
62.20
Other Liabilities
677.30
709.10
518.00
467.60
400.10
Total Liabilities
2,692.20
2,474.30
1,829.50
1,746.50
1,643.40
Common Equity (Total)
3,140.70
2,727.80
1,001.00
824.80
606.10
Total Shareholders' Equity
1,189.60
776.60
539.10
362.90
144.30
Total Equity
2,015.10
1,753.60
1,618.50
1,567.40
1,517.20
Liabilities & Shareholders' Equity
677.10
720.70
211.00
179.10
126.20
Accumulated Minority Interest
825.60
977.00
1,079.30
1,204.50
1,372.90
Preferred Stock (Carrying Value)
1,951.10
1,951.10
461.80
461.80
461.80

About MultiCell Technologies

View Profile
Address
68 Cumberland Street
Woonsocket Rhode Island 02895
United States
Employees -
Website http://www.multicelltech.com
Updated 07/08/2019
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. Its therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company was founded on April 28, 1970 and is headquartered in Woonsocket, RI.